Integer Holdings (ITGR) Cash from Financing Activities (2010 - 2026)
Integer Holdings (ITGR) reported Cash from Financing Activities of $3.8 million for Q2 2026, down 97.47% on a YoY basis from $151.6 million in Q2 2025, and up 106.21% sequentially from -$61.7 million in Q4 2025.
Integer Holdings (ITGR) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Integer Holdings (ITGR) has 17 years of Cash from Financing Activities data on file, last reported at $3.8 million in Q2 2026.
- For the quarter ending Q2 2026, Cash from Financing Activities fell 97.47% year-over-year to $3.8 million; the trailing twelve-month figure through Apr 2026 stood at -$104.2 million (down 6591.59% YoY), and the FY2025 full-year result was $43.6 million, up 226.99% from the prior year.
- Cash from Financing Activities improved to $3.8 million in Q2 2026, from -$61.7 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $163.3 million in Q1 2024 to a low of -$82.3 million in Q4 2024.
- A 5-year average of $8.0 million and a median of -$10.7 million in 2025 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities surged 3321.4% in 2023 and sank 569.69% in 2024, its largest moves.
- Tracing ITGR's Cash from Financing Activities over 5 years: stood at -$13.9 million in 2022, then soared by 225.74% to $17.5 million in 2023, then slumped by 569.69% to -$82.3 million in 2024, then increased by 25.01% to -$61.7 million in 2025, then jumped by 106.21% to $3.8 million in 2026.
- Business Quant data shows ITGR's Cash from Financing Activities at $3.8 million in Q2 2026, -$61.7 million in Q4 2025, and -$10.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 17.31 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -1.51 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | -888.00 Mn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | -260.00 Mn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | -451.20 Mn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | -25.00 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | -26.93 Mn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 21.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Integer Holdings | 3.34 Bn | 3.33 Bn | 109.60 Mn | 3.83 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 3.83 Mn |
| Apr 3, 2026 | 3.83 Mn |
| Dec 31, 2025 | -61.72 Mn |
| Dec 31, 2025 | -61.72 Mn |
| Sep 26, 2025 | -10.71 Mn |
| Sep 26, 2025 | -10.71 Mn |
| Jun 27, 2025 | -35.59 Mn |
| Jun 27, 2025 | -35.59 Mn |
| Mar 28, 2025 | 151.58 Mn |
| Mar 28, 2025 | 151.58 Mn |
| Dec 31, 2024 | -82.30 Mn |
| Dec 31, 2024 | -82.30 Mn |
| Sep 27, 2024 | -43.14 Mn |
| Sep 27, 2024 | -43.14 Mn |
| Jun 28, 2024 | -24.53 Mn |
| Jun 28, 2024 | -24.53 Mn |
| Mar 29, 2024 | 163.29 Mn |
| Mar 29, 2024 | 163.29 Mn |
| Dec 31, 2023 | 17.52 Mn |
| Dec 31, 2023 | 17.52 Mn |